2022
Impact of Chemoembolic Regimen on Immune Cell Recruitment and Immune Checkpoint Marker Expression following Transcatheter Arterial Chemoembolization in a VX2 Rabbit Liver Tumor Model
Berz AM, Santana JG, Iseke S, Gross M, Pekurovsky V, Laage Gaupp F, Savic LJ, Borde T, Gottwald LA, Boustani AM, Gebauer B, Lin M, Zhang X, Schlachter T, Madoff DC, Chapiro J. Impact of Chemoembolic Regimen on Immune Cell Recruitment and Immune Checkpoint Marker Expression following Transcatheter Arterial Chemoembolization in a VX2 Rabbit Liver Tumor Model. Journal Of Vascular And Interventional Radiology 2022, 33: 764-774.e4. PMID: 35346859, PMCID: PMC9344951, DOI: 10.1016/j.jvir.2022.03.026.Peer-Reviewed Original ResearchConceptsTranscatheter arterial chemoembolizationCytotoxic T-lymphocyte-associated protein 4Rabbit liver tumor modelConventional TACEImmune checkpoint marker expressionLiver tumor modelVX2 rabbit liver tumor modelArterial chemoembolizationBicarbonate infusionImmune responseDifferentiation 3T-lymphocyte-associated protein 4Conventional transcatheter arterial chemoembolizationTumor modelCell death protein 1Marker expressionIntratumoral T cellsImmune checkpoint markersT cell infiltrationDeath protein 1Antigen-presenting cellsImmune cell recruitmentNew Zealand white rabbitsZealand white rabbitsAPC infiltration
2021
Comparison of metabolic and immunologic responses to transarterial chemoembolization with different chemoembolic regimens in a rabbit VX2 liver tumor model
Doemel LA, Santana JG, Savic LJ, Gaupp FML, Borde T, Petukhova-Greenstein A, Kucukkaya AS, Schobert IT, Hamm CA, Gebauer B, Walsh JJ, Rexha I, Hyder F, Lin M, Madoff DC, Schlachter T, Chapiro J, Coman D. Comparison of metabolic and immunologic responses to transarterial chemoembolization with different chemoembolic regimens in a rabbit VX2 liver tumor model. European Radiology 2021, 32: 2437-2447. PMID: 34718844, PMCID: PMC9359419, DOI: 10.1007/s00330-021-08337-3.Peer-Reviewed Original ResearchConceptsDrug-eluting embolicsImmune cell infiltrationAntigen-presenting cellsBicarbonate infusionConventional TACEDEE-TACETransarterial chemotherapyCell infiltrationImmune cellsPeritumoral infiltrationT lymphocytesIntratumoral immune cell infiltrationTumor modelRabbit VX2 liver tumor modelImmunological tumor microenvironmentVX2 liver tumor modelIntra-arterial therapyIntra-arterial treatmentRabbit VX2 tumor modelLiver tumor modelTumor-bearing rabbitsVX2 tumor modelMann-Whitney U testIntratumoral presenceTransarterial chemoembolization
2020
Prospective study of Lipiodol distribution as an imaging marker for doxorubicin pharmacokinetics during conventional transarterial chemoembolization of liver malignancies
Savic LJ, Chapiro J, Funai E, Bousabarah K, Schobert IT, Isufi E, Geschwind JH, Stark S, He P, Rudek MA, Perez Lozada JC, Ayyagari R, Pollak J, Schlachter T. Prospective study of Lipiodol distribution as an imaging marker for doxorubicin pharmacokinetics during conventional transarterial chemoembolization of liver malignancies. European Radiology 2020, 31: 3002-3014. PMID: 33063185, DOI: 10.1007/s00330-020-07380-w.Peer-Reviewed Original ResearchConceptsConventional transarterial chemoembolizationProspective clinical trialsTumor responseConventional TACEAdverse eventsTransarterial chemoembolizationLiver malignanciesClinical trialsMarker predictiveTumor volumeExact testChild-Pugh B classVolumetric tumor responseChild-Pugh BPeak concentrationNon-compartmental analysisFisher's exact testDose normalizationQuantitative European AssociationStandard non-compartmental analysisTime-concentration curveLiver criteriaLobar distributionDoxorubicin pharmacokineticsNeuroendocrine metastases
2016
Advanced-stage hepatocellular carcinoma with portal vein thrombosis: conventional versus drug-eluting beads transcatheter arterial chemoembolization
Gorodetski B, Chapiro J, Schernthaner R, Duran R, Lin M, Lee H, Lenis D, Stuart EA, Nonyane BA, Pekurovsky V, Tamrazi A, Gebauer B, Schlachter T, Pawlik TM, Geschwind JF. Advanced-stage hepatocellular carcinoma with portal vein thrombosis: conventional versus drug-eluting beads transcatheter arterial chemoembolization. European Radiology 2016, 27: 526-535. PMID: 27277261, PMCID: PMC5470590, DOI: 10.1007/s00330-016-4445-9.Peer-Reviewed Original ResearchConceptsMedian overall survivalPortal venous thrombosisAdvanced-stage hepatocellular carcinomaConventional TACEDEB-TACEHepatocellular carcinomaOverall survivalAdverse eventsBeads TACEDrug-eluting bead transcatheter arterial chemoembolizationConventional trans-arterial chemoembolizationPropensity scoreDrug-eluting beads TACECommon adverse eventsConclusionOur retrospective studyEqual safety profileChild-Pugh classMethodsThis retrospective analysisPortal vein thrombosisPost-embolization syndromeTranscatheter arterial chemoembolizationStage hepatocellular carcinomaTrans-arterial chemoembolizationSub-group analysisArterial chemoembolization